BRCA2 testing and BRCA gene screening help identify inherited genetic changes in the BRCA1 and BRCA2 genes that may increase a person's risk of developing certain cancers, particularly breast and ovarian cancer. These tests can help individuals understand their inherited cancer risk and support decisions about screening, preventive care, and treatment. MedGenome offers genetic testing services that can help healthcare professionals investigate inherited cancer-associated variants and provide information relevant to personalised medical care. BRCA testing is an important part of hereditary cancer risk assessment, especially for individuals with a strong family history of breast, ovarian, prostate, or pancreatic cancer. Understanding who may benefit from testing, how the procedure works, and what the results mean can help patients make informed decisions with guidance from a qualified healthcare professional or genetic counsellor.
What Is BRCA2 Testing?
BRCA2 testing is a genetic test that examines the BRCA2 gene for variants associated with an increased risk of certain cancers. The BRCA2 gene helps produce a protein involved in repairing damaged DNA. When a person inherits a pathogenic variant in this gene, the body's ability to repair certain types of DNA damage may be affected, potentially increasing the risk of cancer over a person's lifetime. BRCA2 testing is generally performed using a blood sample or saliva sample. The laboratory analyses the DNA to identify relevant genetic variants. A pathogenic BRCA2 variant does not mean that a person definitely will develop cancer. It indicates an increased inherited risk that should be interpreted alongside family history, age, medical history, and other risk factors.
What Is BRCA Gene Screening?
BRCA gene screening usually refers to testing for inherited variants in the BRCA1 and BRCA2 genes. These genes play important roles in repairing damaged DNA and maintaining genomic stability. Although BRCA1 and BRCA2 have related functions, they are distinct genes. Testing may examine one gene or both, depending on the clinical situation and the test selected. BRCA gene screening can help identify people who may benefit from enhanced cancer surveillance, risk-reducing measures, or genetic counselling. In people already diagnosed with certain cancers, BRCA testing may also help guide treatment decisions. It is important to distinguish inherited BRCA testing from tumour testing. Inherited testing examines DNA usually obtained from blood or saliva, while tumour testing examines genetic alterations in cancer tissue or sometimes circulating tumour DNA. A BRCA alteration found in a tumour does not automatically mean it was inherited.
Why Is BRCA2 Testing Important?
BRCA2 testing can provide useful information about inherited cancer risk and help guide medical decisions.
1. Assessing Breast Cancer Risk
Inherited pathogenic variants in BRCA2 are associated with an increased risk of breast cancer. Identifying a variant can help doctors discuss appropriate surveillance and preventive options. Men can also develop BRCA2-associated breast cancer, although the condition is less common than breast cancer in women.
2. Understanding Ovarian Cancer Risk
BRCA2 variants are associated with an increased risk of ovarian cancer. Testing may help individuals and their healthcare providers discuss appropriate risk management and whether preventive interventions should be considered.
3. Evaluating Prostate Cancer Risk
Inherited BRCA2 variants can increase the risk of prostate cancer, including certain aggressive forms. Testing may be considered for selected individuals based on personal and family history.
4. Assessing Pancreatic Cancer Risk
BRCA2 variants are also associated with an increased risk of pancreatic cancer. The need for additional screening depends on individual risk factors, family history, and specialist recommendations.
5. Supporting Treatment Decisions
For people diagnosed with certain cancers, BRCA testing may identify biomarkers relevant to targeted medicines, including PARP inhibitors in appropriate clinical settings. A genetic result does not determine treatment on its own. Doctors consider the cancer type, disease stage, previous treatments, and other clinical findings before making recommendations.
Who Should Consider BRCA Gene Screening?
BRCA testing may be appropriate for people with personal or family histories that suggest an inherited cancer predisposition. A healthcare professional may discuss testing when someone has:
-
A strong family history of breast or ovarian cancer.
-
Breast cancer diagnosed at a young age.
-
Male breast cancer.
-
Ovarian, fallopian tube, or primary peritoneal cancer.
-
Certain types of prostate or pancreatic cancer.
-
A known pathogenic BRCA1 or BRCA2 variant in the family.
Testing may also be considered for people who already have cancer when the results could influence treatment. These examples are not an exhaustive list. Eligibility criteria vary according to clinical guidelines, the type of cancer, and the individual's circumstances. Genetic counselling can help determine whether BRCA testing or a broader hereditary cancer panel is most appropriate.
How Is the BRCA2 Test Performed?
BRCA testing is generally straightforward and does not usually require surgery.
Step 1: Genetic Counselling
A healthcare professional reviews the patient's personal and family history and explains what the test can and cannot reveal. This discussion may include the possible implications for biological relatives.
Step 2: Sample Collection
A blood sample is commonly used, although some laboratories also accept saliva or other validated sample types.
Step 3: Laboratory Genetic Analysis
The laboratory analyses the BRCA1 and BRCA2 genes to identify relevant genetic variants. Depending on the test, analysis may include sequencing and methods for detecting larger deletions or duplications.
Step 4: Report Interpretation
The laboratory classifies the findings according to available evidence. A qualified healthcare professional or genetic counsellor explains the result and discusses any appropriate next steps. The turnaround time depends on the laboratory, test complexity, and sample requirements. Patients should confirm the expected reporting time before testing.
What Do BRCA2 Test Results Mean?
BRCA test results are commonly classified according to the clinical significance of any detected variant.
| Result | General meaning |
|---|---|
| Pathogenic variant | A genetic change known to be associated with increased cancer risk |
| Likely pathogenic variant | A genetic change strongly suspected to be associated with increased risk |
| Variant of uncertain significance (VUS) | Evidence is insufficient to determine whether the variant increases risk |
| Negative result | No relevant variant was identified within the scope of the test |
A pathogenic or likely pathogenic result may lead to recommendations for enhanced surveillance, preventive care, or discussion of risk-reducing options. A negative result does not always eliminate inherited cancer risk, particularly when there is a strong family history or a known familial variant that was not adequately assessed. A variant of uncertain significance should not be treated as a confirmed cancer-risk mutation or used alone to justify major preventive decisions.
BRCA2 Testing by MedGenome
MedGenome provides genetic testing and genomic analysis services that can support the investigation of inherited conditions and cancer-associated genetic variants. For individuals considering BRCA testing, it is important to confirm whether the selected MedGenome service examines BRCA1 and BRCA2 alone or includes additional genes associated with hereditary cancer. When discussing testing with MedGenome or a healthcare professional, ask about:
-
Whether the test covers both BRCA1 and BRCA2.
-
Whether sequencing and deletion or duplication analysis are included.
-
Whether the test is intended for inherited risk assessment or tumour profiling.
-
The sample requirements, current price, and expected turnaround time.
-
Whether genetic counselling is available before and after testing.
The appropriate test depends on the patient's medical history, family history, and the clinical purpose of testing. A specialist can help determine whether targeted BRCA testing or a broader hereditary cancer panel is more suitable.
What Are the Benefits of BRCA Gene Screening?
BRCA gene screening can provide several benefits when performed for an appropriate clinical reason. Better understanding of inherited risk: Testing may identify a genetic predisposition that is not apparent from symptoms alone. Personalised surveillance: Results can help doctors recommend an appropriate cancer surveillance strategy based on the individual's risk. Preventive care discussions: People with pathogenic variants can discuss available risk-reducing options with qualified specialists. Treatment planning: In certain cancer settings, BRCA findings may help determine whether targeted treatments are appropriate. Information for family members: Because inherited BRCA variants can be passed through families, testing may help biological relatives decide whether they should consider genetic counselling or testing. However, BRCA screening cannot predict with certainty whether someone will develop cancer, and not every person with a pathogenic variant will have the same risk.
What Is the Difference Between BRCA Testing and General Genetic Testing?
| Feature | BRCA testing | General genetic testing |
|---|---|---|
| Main focus | BRCA1 and BRCA2 genes | One or more genes, depending on the test |
| Primary purpose | Assess inherited cancer risk or support selected treatment decisions | Investigate inherited disorders, disease risk, or other genetic questions |
| Sample | Usually blood or saliva for inherited testing | Blood, saliva, tissue, or other suitable samples |
| Clinical use | Cancer risk assessment and selected oncology decisions | Varies by condition and purpose |
| Scope | Limited to the genes and variants assessed | May cover one gene, a panel, exome, or broader genomic regions |
BRCA testing may be performed as a standalone test or as part of a multigene hereditary cancer panel. The choice depends on the patient's history and the likelihood of other inherited cancer-related genes being involved.
Frequently Asked Questions About BRCA2 Testing
Is BRCA2 testing only for women?
No. BRCA2 testing can be relevant to both women and men because inherited variants can increase the risk of several cancers, including breast, prostate, and pancreatic cancer.
Does a positive BRCA2 test mean cancer will develop?
No. A pathogenic BRCA2 variant indicates an increased inherited risk, not certainty that cancer will occur. Risk management depends on the specific variant, personal history, family history, and medical guidance.
Is BRCA gene screening painful?
Inherited BRCA testing usually requires a blood sample or saliva sample. Blood collection may cause brief discomfort, while saliva collection is generally non-invasive.
Can BRCA testing help guide cancer treatment?
Yes. In certain cancers, BRCA findings may help doctors assess whether targeted medicines, including PARP inhibitors, are appropriate. Treatment decisions require consideration of the complete clinical picture.
Does MedGenome offer BRCA testing?
MedGenome provides genetic testing and genomic analysis services. Patients should confirm the availability, scope, cost, and suitability of the specific BRCA1 and BRCA2 test with the provider or their treating clinician.
Should family members undergo testing if a BRCA variant is found?
When a pathogenic or likely pathogenic inherited variant is identified, genetic counselling may help biological relatives understand their potential risk and decide whether targeted testing is appropriate.
Conclusion
BRCA2 testing and BRCA gene screening can help identify inherited genetic variants associated with an increased risk of breast, ovarian, prostate, and pancreatic cancers. The results may support personalised surveillance, preventive care discussions, family risk assessment, and selected cancer treatment decisions. MedGenome offers genetic testing and genomic analysis services that may support the evaluation of inherited cancer-related variants. Before testing, individuals should discuss the appropriate test, its limitations, and the possible implications of the results with a qualified healthcare professional or genetic counsellor. Understanding inherited cancer risk can help people make informed medical decisions, but genetic testing should always be interpreted in the context of personal health, family history, and established clinical guidance. Medical disclaimer: This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.